RE:RE:RE:RE:gv...MACE vs. QoL vs. Lipitor-Crestor or 208...Of course RVX would like RVX-208 to be prescribed for all of these! Results of BETonMACE and results of the Emerald Logic Facet analysis should be helpful. However, keep in mind that MACE risk is highest, and hence RVX-208 efficacy to reduce MACE greatest in the high CVD risk low HDL, high LDL, diabetic population. Your other pateint subgroups have less CVD risk factors and less MACE risk. Any phase 3 trial for these other subgroups might require longer and larger trials. This latter statement assumes that RVX-208 will initially be approved and prescribed for the low HDL, high LDL diabetics only and that FDA and EMA wouldn't initially approve for other subgroups without additional trials. Also, if you can treat the root cause of hypertension, and that is your only CVD risk factor, then that should be the treatment target. Same logic for diabetes, obesity, inflammation.
The MACE post hoc analysis did also show that patients with chronic kidney disease or high CRP benefited more than the general ASSURE / SUSTAIN treatment population. I don't think we ever saw the RRR for all patient subgroups, i.e. split by statin type, statin dose and HDL level like we saw for the ASSURE IVUS plaque volume data. RVX has done this for sure and you bet they know where you place their money on the table.
BDAZ